Literature DB >> 9635950

Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection.

M Shibata1, T Morizane, T Uchida, T Yamagami, Y Onozuka, M Nakano, K Mitamura, Y Ueno.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) commonly develops in patients with chronic hepatitis or cirrhosis of the liver caused by hepatitis-C-virus (HCV) infection. We prospectively studied whether irregular regeneration of hepatocytes is a risk factor for HCC in these patients.
METHODS: 242 patients were enrolled after liver biopsy and followed up by ultrasonographic scanning every 3 months. We examined age, sex, platelet count, the diagnosis of cirrhosis or chronic hepatitis, liver-cell dysplasia, and irregular regeneration. We classified irregular regeneration as slight or severe, based on histological expression of pleiomorphism, anisocytosis, bulging, and map-like distribution of hepatocytes.
FINDINGS: 37 of 63 patients with cirrhosis and 26 of 179 with chronic hepatitis were judged to have severe irregular regeneration. HCC was diagnosed in 33 of 63 patients with cirrhosis (29 had severe irregular regeneration) and 12 of 179 patients with chronic hepatitis (11 had severe irregular regeneration) during mean follow-up of 5.5 years (SD 4.1; range 1-16). Multivariate analysis with a proportional-hazards model showed severe irregular regeneration (relative risk 15.1 [95% CI 5.6-40.7], p<0.0001) and a diagnosis of cirrhosis (3.8 [1.7-8.2], p=0.0008) to be significant risk factors for HCC. Within the diagnostic categories, irregular regeneration was also significant (cirrhosis 6.8 [2.1-21.9], p=0.0014; chronic hepatitis 28.5 [2.9-276.4], p=0.0038).
INTERPRETATION: We recommend that liver biopsy to look for irregular regeneration should be done in patients with HCV-related chronic liver diseases. Those with severe irregular regeneration should be followed up carefully.

Entities:  

Mesh:

Year:  1998        PMID: 9635950     DOI: 10.1016/S0140-6736(97)08002-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

1.  Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.

Authors:  Hiroshi Matsumura; Kazushige Nirei; Hitomi Nakamura; Teruhisa Higuchi; Yasuo Arakawa; Masahiro Ogawa; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

Review 2.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

3.  Clinicopathological features of recurrence in patients after 10-year disease-free survival following curative hepatic resection of hepatocellular carcinoma.

Authors:  Masaki Kaibori; Shoji Kubo; Hiroaki Nagano; Michihiro Hayashi; Seiji Haji; Takuya Nakai; Morihiko Ishizaki; Kosuke Matsui; Takahiro Uenishi; Shigekazu Takemura; Hiroshi Wada; Shigeru Marubashi; Koji Komeda; Fumitoshi Hirokawa; Yasuyuki Nakata; Kazuhisa Uchiyama; A-Hon Kwon
Journal:  World J Surg       Date:  2013-04       Impact factor: 3.352

Review 4.  Clinical significance of cell cycle inhibitors in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda; Toshifumi Wakai; Masayuki Kubota; Masaaki Takamura; Satoshi Yamagiwa; Yutaka Aoyagi; Mami Osawa; Shun Fujimaki; Ayumi Sanpei; Takuya Genda; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2013-05-03       Impact factor: 2.309

Review 5.  Deciphering the nuclear bile acid receptor FXR paradigm.

Authors:  Salvatore Modica; Raffaella M Gadaleta; Antonio Moschetta
Journal:  Nucl Recept Signal       Date:  2010-11-19

6.  Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma.

Authors:  Mario Uccello; Giulia Malaguarnera; Elisa M Pelligra; Antonio Biondi; Francesco Basile; Massimo Motta
Journal:  Indian J Med Paediatr Oncol       Date:  2011-04

7.  Viral hepatitis and hepatocellular carcinoma.

Authors:  Peter P Michielsen; Sven M Francque; Jurgen L van Dongen
Journal:  World J Surg Oncol       Date:  2005-05-20       Impact factor: 2.754

8.  Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.

Authors:  Kazushige Nirei; Hiroshi Matsumura; Mariko Kumakawa; Naoki Matsumoto; Hitomi Nakamura; Hiroaki Yamagami; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  Int J Med Sci       Date:  2017-01-01       Impact factor: 3.738

Review 9.  Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist.

Authors:  Alberto Quaglia
Journal:  J Hepatocell Carcinoma       Date:  2018-11-08

10.  A miRNA-mediated attenuation of hepatocarcinogenesis in both hepatocytes and Kupffer cells.

Authors:  Yan Tian; Mingfeng Zhang; Mingjie Fan; Haixia Xu; Shunquan Wu; Sailan Zou; Yangmeng Wang; Dongmei Tang; Chunyan Zhang; Weidong Han; Hua Yu; Xianghui Fu; Wendong Huang
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-28       Impact factor: 10.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.